Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News20 hours agoNorth Lakes home erupts in flames as woman rushed from burning house with injuries
-
General24 hours agoOrganisers refuse offer to move Agnes Water festival off rainbow bee-eater bird nesting site
-
Noosa News23 hours agoQueensland Police pilot who claimed $183k salary couldn’t support his family is denied $53k payout
-
Noosa News21 hours agoChild safety boss says Unify IT system was launched for budgetary reasons